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Abstract
Adult-type granulosa cell tumor (aGCT) is a rare malignant ovarian sex cord-stromal tumor, 
harboring recurrent FOXL2 c.C402G/p.C134W hotspot mutations in 97% of cases. These tumors 
are considered to have a favorable prognosis, however aGCTs have a tendency for local spread and 
late recurrences, which are associated with poor survival rates. We sought to determine the genetic 
alterations associated with aGCT disease progression. We subjected primary non-recurrent aGCTs 
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(n=7), primary aGCTs that subsequently recurred (n=9) and their matched recurrences (n=9), and 
aGCT recurrences without matched primary tumors (n=10) to targeted massively parallel 
sequencing of ≥410 cancer-related genes. In addition, 3 primary non-recurrent aGCTs and 9 aGCT 
recurrences were subjected to FOXL2 and TERT promoter Sanger sequencing analysis. All aGCTs 
harbored the FOXL2 C134W hotspot mutation. TERT promoter mutations were found to be 
significantly more frequent in recurrent (18/28, 64%) than primary aGCTs (5/19, 26%, p=0.017). 
In addition, mutations affecting TP53, MED12 and TET2 were restricted to aGCT recurrences. 
Pathway annotation of altered genes demonstrated that aGCT recurrences displayed an enrichment 
for genetic alterations affecting cell cycle pathway-related genes. Analysis of paired primary and 
recurrent aGCTs revealed that TERT promoter mutations were either present in both primary 
tumors and matched recurrences or were restricted to the recurrence and absent in the respective 
primary aGCT. Clonal composition analysis of these paired samples further revealed that aGCTs 
display intra-tumor genetic heterogeneity and harbor multiple clones at diagnosis and relapse. We 
observed that in a subset of cases, recurrences acquired additional genetic alterations not present in 
primary aGCTs, including TERT, MED12 and TP53 mutations and CDKN2A/B homozygous 
deletions. Albeit harboring relatively simple genomes, our data provide evidence to suggest that 
aGCTs are genetically heterogeneous tumors and that TERT promoter mutations and/or genetic 
alterations affecting other cell cycle-related genes may be associated with disease progression and 
recurrences.
INTRODUCTION
Adult-type granulosa cell tumors (aGCTs) of the ovary are a rare form of ovarian cancer 
(<5%) characterized by rather simple genomes and by the presence of recurrent FOXL2 
p.C134W somatic missense mutations in ≥97% of cases [1–3]. Despite their indolent growth 
and overall good prognosis, recurrences occur in 10 to 30% of aGCTs [4–7]. These rare 
tumors exhibit long latency periods, with a median time to first recurrence of 4-7 years [4–
6], with late recurrences reported up to 20 to 30 years following initial diagnosis [8]. Hence, 
the natural history of aGCTs poses therapeutic challenges, requiring long-term follow-up 
[5,9,10].
Somatic TERT promoter mutations (C228T and C250T), associated with telomerase 
activation, have been reported at high frequency in cancers (12% overall) [11], including 
gynecologic malignancies such as ovarian clear cell carcinomas (16%) [12,13]. In addition, 
recent studies have reported a significantly higher frequency of the TERT C228T promoter 
hotspot mutations in recurrent (41-67%) than in primary aGCTs (22-29%) [14,15]. Patients 
with primary aGCTs harboring TERT promoter hotspot mutations were also found to have a 
significantly worse overall survival than those with wild-type TERT [14]. Furthermore, 
KMT2D inactivating mutations have been reported to be associated with recurrences in 
aGCTs [16].
Although TERT promoter and KMT2D mutations appear to provide the basis for recurrences 
in a subset of aGCTs, the genetic basis of the clinical behavior in a substantial proportion of 
recurrent aGCTs has not been defined to date. Here, we sought to compare the repertoire of 
somatic genetic alterations of i) primary aGCTs that did not recur within at least four years 
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of follow-up, ii) primary aGCTs that recurred and iii) aGCT recurrences. Furthermore, given 
that samples from primary aGCTs and their respective relapses were available, we have also 
compared the TERT mutation status between paired primary and recurrent aGCTs, and 
investigated whether aGCTs would display intra-tumor genetic heterogeneity and if specific 
genetic alterations would be selected during progression from primary tumor to recurrence.
MATERIALS AND METHODS
Subjects and samples
Following approval by the Institutional Review Board (IRB) of the authors’ institutions, we 
retrieved representative hematoxylin-and-eosin (H&E) and unstained tissue sections from 
formalin-fixed paraffin embedded (FFPE) aGCTs from Memorial Sloan Kettering Cancer 
Center (MSKCC, NY, USA), Fudan University Cancer Center (Shanghai, China), Hospital 
Universitario de Bellvitge (Barcelona, Spain), Hospital Universitario Arnau de Vilanova 
(Lleida, Spain) and Cleveland Clinic (OH, USA). Patient consents were obtained according 
to the protocols approved by the local IRBs of the authors’ institutions. Samples were 
anonymized prior to analysis. Samples from 40 cases were reviewed by eight pathologists 
(RB, SES, MV, CGP, XM-G, BPR, JSR-F and DFD) following the criteria put forward by 
the World Health Organization [17]. Only cases where a consensus diagnosis of aGCT was 
achieved were included in this study (n=38), and two cases were excluded. Patients were 
defined as having primary non-recurrent aGCTs if no recurrence was detected within at least 
48 months of follow-up, based on the median and range of time-to-recurrence of aGCTs 
previously reported [4–6]. Our final series included 47 samples from 38 patients: i) primary 
non-recurrent aGCTs (n=10), ii) primary aGCTs that subsequently recurred (n=9) and their 
matched recurrences (n=9 from 9 patients), and aGCT recurrences without matched primary 
tumors (n=19; Table 1 and Supplementary Table S1). Surgical staging was performed 
according to the 2014 International Federation of Gynecology and Obstetrics (FIGO) system 
[18]
Targeted capture massively parallel sequencing using the Memorial Sloan Kettering-
Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT) [11,19] was 
performed on tumor-normal pairs from 26 patients, including 7 primary non-recurrent 
aGCTs, 9 primary recurrent aGCTs and their matched recurrences, and 10 aGCT 
recurrences. The remaining 3 primary non-recurrent aGCTs and 9 aGCT recurrences from 
12 additional patients did not yield sufficient DNA for MSK-IMPACT sequencing, and, 
therefore, were subjected to Sanger sequencing analyses to assess the presence of FOXL2 
and TERT promoter hotspot mutations (see below; Supplementary Table S1).
Microdissection and DNA extraction
Representative sections of tumor tissue samples were microdissected under a 
stereomicroscope (Olympus SZ61) to ensure a tumor cell content >80%, as previously 
described [20,21]. DNA from tumor and matched normal tissues was extracted using the 
DNeasy Blood and Tissue Kit (Qiagen) according to manufacturers’ instructions. DNA of 
sufficient quantity/ quality was obtained for Sanger sequencing for all 38 cases (47 samples) 
and for targeted massively parallel sequencing for 26 cases (35 samples; see below).
Da Cruz Paula et al. Page 3













Assessment of FOXL2 and TERT promoter hotspot mutations by Sanger sequencing
PCR amplification of FOXL2 and TERT promoter hotspot loci was performed using the 
AmpliTaq Gold 360 Master Mix kit (Life Technologies, ThermoFisher Scientific) using 
previously described primers [22,23]. PCR fragments were cleaned using ExoSAP It 
(ThermoFisher Scientific) and Sanger sequenced as previously described [22].
Targeted massively parallel sequencing
Microdissected tumor and matched normal DNA samples from primary non-recurrent 
aGCTs (n=7), primary recurrent aGCTs (n=9) and matched recurrences (n=9), and aGCT 
recurrences (n=10) were subjected to MSK-IMPACT sequencing of 410-468 cancer-related 
genes, as previously described [19,24]. Sequencing data were processed and analyzed as 
previously described [21,24]. In brief, reads were aligned to the reference human genome 
GRCh37 using the Burrows-Wheeler Aligner (BWA v0.7.15) [25]. Local realignment, 
duplicate removal and base quality recalibration were performed using the Genome Analysis 
Toolkit (GATK, v3.7) [26]. Somatic single nucleotide variants (SNVs) were detected by 
MuTect (v1.0) [27], and small insertions and deletions (indels) were detected using a 
combination of Strelka (v2.0.15) [28], VarScan2 (v2.3.7) [29], Lancet (v1.0.0) [30], Scalpel 
(v0.5.3) [31] and Platypus [32]. Pathogenic mutations were defined as variants that were 
deleterious and/or mutational hotspots. In addition, mutations that were identified in the 
primary or recurrent tumor from a given patient were subsequently interrogated in the 
matched respective primary or recurrent sample using mpileup from SAMtools mpileup 
(version 1.2 htslib 1.2.1) [33]. Allele-specific copy number alterations (CNAs) and loss-of-
heterozygosity (LOH) were defined using FACETS [34], as previously described [20,21]. 
The fraction of the genome altered was computed from the CNAs obtained from FACETS. 
The cancer cell fraction (CCF) of each mutation was determined using ABSOLUTE (v1.0.6) 
[35], as previously described [20,24]. A combination of mutation function predictors was 
employed to define the potential functional impact of each missense SNV, as previously 
described [20,21,36]. Mutational hotspots were assigned according to Chang et al. [37]. The 
median depth of coverage of tumor and normal samples was 518x (range 120x–1223x) and 
366x (range 117x-510x), respectively (Supplementary Table S2).
Pathway analyses
A MSigDB and DAVID pathway analysis was performed based on genes affected by non-
synonymous pathogenic somatic mutations, amplifications or homozygous deletions in 
primary non-recurrent aGCTs (n=7), primary aGCTs (n=9) and matched recurrences (n=9) 
and aGCT recurrences (n=10) [38]. Pathways found to be significantly enriched (p<0.01) 
were selected as previously reported [39]. Additionally, a mutual exclusivity analysis was 
performed using combinations of mutually exclusive alterations (CoMET) with the use of a 
pair-wise Fisher’s exact test to detect the presence of significant pairs of genes [40].
Mutation-based tree construction
The mutation-based trees of the primary and matched aGCT recurrences were constructed 
using Treeomics [41] based on all synonymous and non-synonymous mutations identified, 
as previously described [24]. For these analyses, a given mutation was considered “shared” 
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if it was present in both the primary and matched aGCT recurrences. We defined mutations 
present only in the primary tumor or only in the recurrence as “private to the primary aGCT” 
and “private to the aGCT recurrence”, respectively.
Statistical analysis
The frequencies of somatic mutations affecting cancer genes in primary and recurrent 
aGCTs were compared using two-tailed Fisher’s exact test. Mutual exclusivity was tested 
using two-tailed Fisher’s exact test. The fraction of genome affected by copy number 
alterations in primary and recurrent aGCTs was evaluated using a Mann-Whitney U test. All 
p-values were two-tailed, and 95% confidence intervals were adopted for all analyses.
RESULTS
Clinico-pathologic features of primary and recurrent aGCTs
Our series encompassed aGCTs from 38 patients, including 10 patients with non-recurrent 
aGCTs (‘primary non-recurrent aGCTs’) and 28 patients with recurrent disease. Of the 28 
patients with recurrent disease, we analyzed samples from the primary tumor (‘primary 
recurrent aGCT’) and matched recurrences from 9 patients, and from the recurrent tumors 
only from 19 patients (‘aGCT recurrences’; Supplementary Table S1).
The median age of patients at aGCT diagnosis was 52.5 years (range 34-87 years) in 
primary non-recurrent aGCTs (n=10), 62 years (range 41-83 years) for patients with primary 
aGCT that developed recurrences (n=9) and 56 years (range 34-89 years) for patients with 
aGCT recurrences without available matched primary tumors (n=19). No significant 
differences in age at diagnosis were observed between primary non-recurrent aGCTs and 
primary aGCTs that recurred (p=0.74, Student’s t-test, Table 1, Supplementary Table S1). 
All patients (10/10, 100%) with primary non-recurrent aGCTs had early stage disease (IA 
and IC) at the time of diagnosis, whereas 1 (11%) and 2 patients (22%) with primary aGCTs 
that recurred had stage II and stage III disease at the time of diagnosis, respectively. No 
significant differences in stage were observed between primary non-recurrent aGCTs and 
primary aGCTs that recurred (p=0.087, Fisher’s exact test), or other clinic-pathologic factors 
assessed (Table 1, Supplementary Table S1).
aGCT recurrences display distinct genomic profiles from primary aGCTs
Consistent with previous reports [2,14,15], all aGCTs analyzed in this study harbored 
FOXL2 p.C134W missense mutations as defined by MSK-IMPACT and/or Sanger 
sequencing (Figure 1A). In addition, we identified recurrent TERT promoter mutations by 
Sanger and/or MSK-IMPACT sequencing, affecting not only the previously described 
C228T hotspot locus but also the C250T locus (Figure 1A). In these 38 aGCTs, a 
significantly higher frequency of TERT promoter mutations was observed in aGCT 
recurrences (18/28, 64%) than in primary non-recurrent and primary recurrent aGCTs (5/19, 
26.3%, p=0.017, Fisher’s exact test, Figure 1A, Table 2). While there was a stepwise 
increase in the frequency of TERT promoter mutations from primary non-recurrent aGCTs 
(2/ 7; 29%) to primary recurrent aGCTs (3/ 9; 33%) and aGCT recurrences (10/ 19; 52%; 
Figure 1B), no significant differences in the TERT hotspot mutation frequency between 
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primary aGCTs with (n=9) and without (n=10) recurrences were found (33% vs 20% 
p=0.434, Fisher’s exact test; Figure 1A, Table 2).
Analysis of the somatic mutation data obtained from MSK-IMPACT further revealed that 
aGCTs overall displayed a relatively low mutation burden, with a median of 3 (range 1-7) 
somatic mutations in the genes analyzed, of which 2 (range 1-6) were non-synonymous 
(Supplementary Table S3). Despite the numerically higher number of somatic mutations 
identified in aGCT recurrences (median 3, range 2-7), no statistically significant differences 
in the mutational burden were observed when compared to primary non-recurrent aGCTs 
(median 2, range 1-5; p=0.47, Fisher’s exact test) or primary recurrent aGCTs (median 2, 
1-5; p=0.86, Fisher’s exact test). Recurrent mutations affecting known cancer-related genes 
such as GNAQ and KMT2C were identified, however none of these were statistically 
different between the groups (Figure 1B). Also, inactivating KMT2D mutations, which have 
been reported to be associated with recurrence in aGCTs [16], were only found in a single 
sample in our study and affected a primary non-recurrent aGCT (aGCT35-P; Figure 1B; 
Supplementary Table S3). In contrast, we identified TP53 pathogenic mutations only in 
aGCT recurrences (16%). Of note, the TP53-mutant aGCT recurrences did not harbor TERT 
promoter mutations (Figure 1B); however formal mutual exclusivity analysis using CoMET 
showed that TERT promoter and TP53 mutations were not significantly mutually exclusive 
in aGCT recurrences (p=0.062, Fisher’s exact test, Figure 2A), likely due to the low number 
of samples/ TP53 mutations. We further found a subclonal pathogenic mutation affecting 
TET2 (5%) that was restricted to an aGCT recurrence lacking a TERT promoter mutation 
(aGCT82-R; Figure 1B, Supplementary Table S1), and STAG2 and IDH1 pathogenic 
mutations in primary recurrent aGCTs (11%) and their matched aGCT recurrences (5%) but 
not in primary non-recurrent aGCTs (0%) (Figure 1B). None of these differences reached 
statistical significance, however, likely due to the small sample size.
When assessing the CNAs in the aGCTs subjected to MSK-IMPACT sequencing, we found 
primary aGCTs and aGCT recurrences to display overall similar copy number profiles with 
similar fractions of the genome altered (primary non-recurrent aGCTs, median 11%, range 
5-48%; primary recurrent aGCTs, median 9%, range 0-91%; aGCT recurrences, median 8%, 
range 0-52%, Figure 2B). Nevertheless, a numerically higher frequency of CDKN2A/B 
homozygous deletions was observed in aGCT recurrences (3/19, 16%) and in primary 
recurrent aGCTs (1/9, 11%) as compared to primary non-recurrent aGCTs (0%). Similarly, 
homozygous deletions of BCL2L11 were also identified in primary recurrent aGCTs (2/9, 
22%) and in aGCT recurrences (2/19, 11%) but not in primary non-recurrent aGCTs (Figure 
1B).
Recurrent aGCTs harbor somatic genetic alterations affecting the cell cycle pathway
Given the distinct genetic alterations observed in primary non-recurrent aGCTs and aGCT 
recurrences, we sought to determine the signaling pathways that are enriched in aGCT 
recurrences. For this, we performed a pathway analysis using the genes that were either 
affected by non-synonymous pathogenic somatic mutations, amplifications or homozygous 
deletions. This analysis revealed that there was an enrichment in cell cycle pathway genes 
that were altered in aGCT recurrences but not in primary aGCTs (Supplementary Table S4). 
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As mentioned above, pathogenic TP53 alterations were solely found in aGCT recurrences 
(Figure 2C, top), whereas CDKN2A/B homozygous deletions were identified in both aGCT 
recurrences and primary recurrent aGCTs but not in primary non-recurrent aGCTs (Figure 
2C, bottom left). In contrast, CDKN1B homozygous deletions were identified at different 
frequencies in primary non-recurrent aGCTs (14%), primary aGCTs that recurred (11%) and 
in aGCT recurrences (5%; Figure 2C, bottom right). These findings suggest that in addition 
to the described TERT promoter mutations [14,15] alterations in cell cycle-related genes and 
apoptosis might also play a role in the progression of aGCTs.
TERT promoter mutations in primary aGCTs and matched recurrences
To investigate the role of TERT promoter mutations in the progression of aGCTs, we next 
assessed the TERT promoter mutation status in primary aGCTs and their matched 
recurrences using MSK-IMPACT and Sanger sequencing. Of the nine pairs of primary and 
recurrent aGCTs included in this study, five harbored TERT mutations in at least one of the 
samples of a given patient based on MSK-IMPACT sequencing (Figure 3). We found that in 
two cases (aGCT77 and aGCT80), the primary lesion lacked TERT promoter mutations, but 
that the matched aGCT recurrences harbored a clonal C250T mutation (aGCT77) or a 
subclonal C228T mutation (aGCT80). This finding provides evidence to suggest that, in 
these cases, TERT mutations were either selected from a minor subclone not detected in the 
sequencing of the primary tumor or were acquired during disease progression. In contrast, 
the primary aGCT18 and aGCT43 both harbored clonal C228T TERT promoter hotspot 
mutations, which were preserved in the respective recurrences. Finally, a subclonal C250T 
was found in both, the primary and matched recurrence of case aGCT76 (Figure 3).
Clonal composition analysis of paired primary and aGCT recurrences
To interrogate the genetic alterations in addition to TERT promoter mutations that might be 
associated with clinical progression of aGCTs, we performed a clonal composition analysis 
of the nine primary aGCTs and their matched recurrences. Our analyses revealed that both 
the primary aGCTs and their matched recurrences shared clonal mutations in FOXL2 
(p.C134W) in all nine cases analyzed (Figure 4, Supplementary Table S2). Furthermore, 
primary tumors and their matched recurrences also shared somatic mutations affecting 
KMT2C (p.A1685S), MYOD1 (p.S260F), KMT2D (p.C5481F), PIK3R1 (p.W624R) and the 
TERT promoter (Figure 4, Supplementary Figure S3). We observed, however, that in a 
subset of cases, the recurrences acquired additional somatic mutations or CNAs not present 
in the primary aGCT: we identified clonal MED12 (aGCT77, p.Q2076dup), clonal SH2D1A 
(aGCT78, p.P97S) and subclonal TET2 (aGCT82, p.C1281Vfs*82) mutations restricted to 
the recurrences. Furthermore, two aGCT recurrences acquired alterations in cell cycle 
related genes such as TP53 mutations (aGCT78, p.F338Lfs*7; aGCT82, p.Y236H) or 
CDKN2A/B homozygous deletions (aGCT79), which were not detected in their respective 
primary tumors (Figure 4).
DISCUSSION
Despite their relatively indolent behavior, management of a subset of aGCTs remains 
challenging due to their unpredictable behavior and late relapses. Identification of markers 
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predictive of disease recurrences/ metastases has been the subject of considerable interest. 
Here we not only confirm the presence of TERT promoter hotspot mutations in aGCTs but 
also find that somatic genetic alterations affecting cell-cycle progression and apoptosis-
related genes may play a role in the progression from primary aGCTs to recurrences.
Recent studies have reported a highly recurrent somatic mutation (C228T) in the promoter 
region of TERT in aGCTs [14,15]. In our study, in addition to the C228T mutation (80%), 
we also identified recurrent C250T TERT hotspot mutations in 20% of the aGCTs harboring 
TERT promoter mutations. Whilst TERT promoter mutations have been reported to be an 
early genetic event in several cancer types [42–44], in aGCTs one study has suggested that 
these mutations are a late event [14]. The overall frequency of TERT promoter hotspot 
mutations in our series was significantly higher in aGCT recurrences than in primary 
aGCTs. TERT promoter mutations have been reported to lead to increased TERT expression 
and telomerase activation, to overcome the proliferative barrier imposed by telomere 
shortening, and to promote both immortalization and tumorigenesis [45]. Of note, the 
analysis of paired primary and recurrent aGCTs revealed that TERT promoter mutations 
were likely acquired during disease progression in two cases (aGCT77 and aGCT80), 
whereas in three cases (aGCT18, aGCT43 and aGCT76) these mutations were present in 
both primary tumors and matched recurrences. These findings suggest that depending on the 
context and activation of other signaling pathways, TERT promoter mutations may either be 
an early event and play a role in the development of more aggressive primary disease, that 
has the potential to spread and recur; or, in other contexts, TERT promoter mutations may be 
a late event and acquired during progression, disease spread or recurrence [14,15]. Further 
studies are required to understand the interplay between TERT promoter mutations and other 
genetic or epigenetic alterations, and TERT’s activation and role in aGCT maintenance and 
progression. It is unlikely, however, that TERT promoter mutation status alone would be the 
sole genetic predictor of recurrence. In our series, only one third of primary aGCTs with 
recurrences harbored a TERT hotspot mutation, as did two primary aGCTs (20%) without 
subsequent recurrences after more than 8 years of follow-up.
In our series, TP53 mutations were identified in 16% of aGCT recurrences but were not 
present in primary aGCTs. Importantly, we observed that these TP53 mutations were 
acquired during disease progression in cases that did not harbor TERT promoter mutations. 
Alexiadis et al. also reported a TP53 mutation in a recurrent aGCT that also lacked TERT 
promoter mutations but they had a lower frequency of TP53 mutations overall in their series 
(4%, 1/22) [15]. Our findings suggest that TP53 may play a role in the progression of 
aGCTs, in particular in those lacking TERT promoter mutations.
Apart from TP53, we observed an enrichment of alterations in cell cycle genes in aGCT 
recurrences, including CDKN2A/B homozygous deletions. Given the small numbers 
assessed, further studies are warranted to define the frequency and role of cell cycle related 
genes in the progression of aGCTs. Whilst homozygous deletions or loss-of-function 
mutations of CDKN2A/B are frequent events in various human primary solid and 
hematopoietic neoplasias [46,47], these have not been previously reported in aGCTs. Gene 
expression analyses comparing wild-type FOXL2 and mutant FOXL2 C402G (p.C134W) 
transfected COV434 aGCT cells in vitro revealed the presence of differentially expressed 
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genes associated with cell death and cell proliferation in mutant FOXL2 cells, such as 
CDKN1A, CDKN2A and CDK6 [48]. Inactivating mutations in the chromatin remodeling 
gene KMT2D have been recently reported to be strongly associated with aGCT recurrences 
[16]. The frequency of KMT2D loss-of-function mutations was very low in the aGCT 
analyzed here (one truncating mutation identified in one primary non-recurrent aGCT35). 
Furthermore, even when taking all non-synonymous KMT2D mutations into account, no 
difference in frequency between primary aGCTs with/ without recurrences and aGCT 
recurrences could be identified.
Clonal composition analysis revealed that primary aGCTs and their matched recurrences, 
despite their generally simple genomes with few mutations and copy number alterations, 
display intra-lesion heterogeneity harboring clonal and subclonal mutations. In the 
progression from primary to metastatic disease, the acquisition of additional mutations, loss 
of heterozygosity of the wild-type allele of a given mutated gene as well as clonal shifts of 
genes affected by somatic mutations have been described [49–51]. Through the analysis of 
paired primary and matched recurrent aGCTs, we found that the acquisition of mutations, 
including those affecting TP53, TET2, MED12 and SH2D1A, was most commonly 
associated with disease progression.
Our study has important limitations. The sample size of the study is small, given the rarity of 
aGCTs, and larger validation studies are warranted. In addition, given the multi-institutional 
nature of our study, survival analyses could not be performed. Furthermore, our findings 
may not be applicable to the general population, given that the majority of the patients 
included in our cohort were treated at tertiary referral centers that tend to see higher risk 
populations. The recurrence rates observed here were similar to those reported in the 
literature, however [5,7]. Given the limited amounts of DNA available from these lesions, 
we restricted our sequencing analysis to 410-468 cancer-related genes. We cannot rule out, 
however, that there are other genes which may play a role in the progression of aGCTs. 
Nonetheless, our findings provide support to the notion that TERT promoter hotspot 
mutations are the most recurrent genetic events affecting aGCTs and might be associated 
with disease progression in a subset of cases. We further identified genetic alterations 
affecting cell cycle-related genes, which may be associated with aGCT progression. Finally, 
our data suggest that whilst aGCTs harbor simple genomes, intra-tumor heterogeneity is 
present in this rare subtype of pure sex-cord tumor.
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Figure 1: Landscape of somatic genetic alterations in cancer-related genes in primary and 
recurrent adult-type granulosa cell tumors of the ovary.
(A) FOXL2 and TERT promoter hotspot mutations in 38 adult-type granulosa cell tumors of 
the ovary (aGCTs) subjected to MSK-IMPACT and/ or Sanger sequencing. Statistical 
significance was evaluated by Fisher’s exact test. (B) Non-synonymous somatic mutations, 
amplifications and homozygous deletions identified in primary adult-type granulosa cell 
tumors (aGCT) using MSK-IMPACT sequencing, including those without (non-recurrent, 
n=7, left) and with (recurrent, n=9, middle) subsequent recurrences, and in aGCT 
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recurrences (n=19, right). Cases are shown in columns and genes in rows. Genetic 
alterations are color-coded according to the legend. Indel, small insertion and deletion; SNV, 
single-nucleotide variant.
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Figure 2: Mutual exclusivity analysis, fraction of the genome altered and genetic alterations 
affecting the cell-cycle pathway in primary and recurrent adult-type granulosa cell tumors of the 
ovary.
(A) Mutual exclusivity analysis between TERT promoter hotspot mutations and TP53 
mutations in adult-type granulosa cell tumor (aGCT) recurrences. The type of mutations is 
color-coded according to the legend. Mutual exclusivity analysis was performed using 
combinations of mutually exclusive alterations (CoMET) and Fisher’s exact test. (B) 
Fraction of the genome altered in primary non-recurrent aGCTs, primary recurrent aGCTs 
and aGCT recurrences. (C) Frequency of loss-of-function somatic genetic alterations 
affecting genes in the canonical cell-cycle pathway. Genes are depicted in blue rectangles, 
and the percentage of primary non-recurrent aGCTs (Prim), primary recurrent aGCTs (Prim 
Rec) and aGCT recurrences (Rec) altered is shown below each gene.
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Figure 3. TERT promoter hotspot mutations in paired primary aGCTs and recurrences.
TERT promoter hotspot mutations and their clonality identified in primary aGCTs (left) and 
their matched recurrences (right) using targeted MSK-IMPACT sequencing. The TERT 
mutations were validated by Sanger sequencing, and the electropherograms of all samples 
are shown. Cancer cell fractions are color coded according to the legends, and clonal 
mutations are depicted by a yellow box. Arrows in electropherograms indicate TERT 
promoter mutations.
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Figure 4: Clonal composition of primary and matched recurrent adult-type granulosa cell 
tumors of the ovary.
Representative hematoxylin and eosin micrographs (magnification, 200x; left), cancer cell 
fractions (clonal frequency) of mutations (top right) and mutation-based trees (bottom right) 
depicting the clonal evolution of matched primary and recurrent adult-type granulosa cell 
tumors (aGCTs) of the ovary for (A) aGCT77, (B) aGCT80, (C) aGCT78, (D) aGCT82 and 
(E) aGCT79. Cancer cell fractions are color-coded according to the legend. Clonal 
mutations are depicted by a yellow box. The length of the trunk and branches of the 
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phylogenetic trees is proportional to the number of shared and private mutations identified in 
primary and recurrent aGCTs. Scale bars, 200 μM. P, primary tumor; R, recurrence; T, 
truncal.
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Table 1:
Clinico-pathological features of ovarian adult-type granulosa cell tumors patients included in this study.
Primary non-recurrent aGCTs 
(n=10) p value
* Primary recurrent aGCTs 
(n=9)
aGCT recurrence without 
matched primary tumors 
(n=19)
Median age (years) 52.5 (34-87) 0.74 62 (41-83) 56 (34-89)






























Primary non-recurrent aGCTs vs primary recurrent aGCTs, using Student’s t-test and Fisher’s exact test. aGCT, adult-type granulosa cell tumor; 
N/A, not applicable.
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Table 2:
TERT promoter mutational status in primary and recurrent adult-type granulosa cell tumors of the ovary.
Clinical presentation aGCTs TERT promoter mutant, n (%) TERT promoter wild-type, n (%) p value*
Primary non-recurrent (n=10) 2 (20%) 8 (80%)
0.434
Primary recurrent (n=9) 3 (33%) 6 (67%)
Primary non-recurrent and primary recurrent (n=19) 5 (26%) 14 (74%)
0.017
Recurrences (n=28) 18 (64%) 10 (36%)
*
Fisher’s exact test. aGCT, adult-type granulosa cell tumor.
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